Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment remaining a challenge despite decades of research. For years, the prostate-specific ...

Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

A study of men with a family history of prostate cancer has discovered an inherited form of prostate cancer. The inherited ...

Study Highlights Mental Well-being Fuels Physical FitnessAccording to a recent study, the tendency to experience positive ...

Prostate cancer (PC) is a prevalent malignancy among males and ranks as the fifth leading cause of cancer-related deaths globally. Factors such as age, ...

Do you consider the cancer measurements to be small, thus making the “observation only” protocol correct? — B.A. Dear B.A.: ...

Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...